Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate,… Read more
Egetis Therapeutics AB (publ) (EGTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.166x
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has a cash flow conversion efficiency ratio of -0.166x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-59.00 Million) by net assets (Skr355.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Egetis Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Egetis Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mayur Uniquoters Ltd
NSE:MAYURUNIQ
|
0.082x |
|
LCY Technology Corp
TW:4989
|
-0.089x |
|
Sport Lisboa e Benfica - Futebol, SAD
LSE:0M7V
|
N/A |
|
Jean Co Ltd
TW:2442
|
-0.062x |
|
Bank Jabar
JK:BJBR
|
-0.231x |
|
Rexon Industrial Corp Ltd
TW:1515
|
-0.095x |
|
Vieworks Co. Ltd
KQ:100120
|
0.079x |
|
Shanghai Taihe Water Environmental Technology Development Co Ltd
SHG:605081
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Egetis Therapeutics AB (publ) (2010–2024)
The table below shows the annual cash flow conversion efficiency of Egetis Therapeutics AB (publ) from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr492.90 Million | Skr-227.90 Million | -0.462x | +9.39% |
| 2023-12-31 | Skr545.60 Million | Skr-278.40 Million | -0.510x | -48.87% |
| 2022-12-31 | Skr506.20 Million | Skr-173.50 Million | -0.343x | -38.84% |
| 2021-12-31 | Skr527.04 Million | Skr-130.11 Million | -0.247x | -15.45% |
| 2020-12-31 | Skr629.63 Million | Skr-134.64 Million | -0.214x | +16.41% |
| 2019-12-31 | Skr244.88 Million | Skr-62.64 Million | -0.256x | +30.13% |
| 2018-12-31 | Skr219.36 Million | Skr-80.31 Million | -0.366x | -28.47% |
| 2017-12-31 | Skr303.71 Million | Skr-86.55 Million | -0.285x | -207.40% |
| 2016-12-31 | Skr389.56 Million | Skr-36.12 Million | -0.093x | +91.29% |
| 2015-12-31 | Skr48.03 Million | Skr-51.15 Million | -1.065x | -133.30% |
| 2014-12-31 | Skr90.66 Million | Skr-41.38 Million | -0.456x | +23.63% |
| 2013-12-31 | Skr46.95 Million | Skr-28.07 Million | -0.598x | -0.89% |
| 2012-12-31 | Skr53.94 Million | Skr-31.96 Million | -0.592x | -260.23% |
| 2011-12-31 | Skr87.53 Million | Skr-14.40 Million | -0.164x | +57.69% |
| 2010-12-31 | Skr6.99 Million | Skr-2.72 Million | -0.389x | -- |